Scholars Central

Conference abstractPublished 2018

Safety of dapagliflozin on 12-derived electrocardiogram in patients with type 2 diabetes mellitus

Authors: Gamze Akkus

Antakya State Hospital, Turkey

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Statement of the Problem: Since cardiovascular complications of Diabetes Mellitus (DM) are life-threatening, treatment of DM must be more attentive. Dapagliflozin is a Sodium Glucose Co-Transporter-2 Inhibitor (SGLT-2) and there was a doubt whether a potential electrolyte imbalance and its electrocardiographic side effects. We aim to determine the safety of dapagliflozin on 12-derived electrocardiogram in patients with type 2 DM. Methodology & Theoretical Orientation: 41 patients (28 male, 13 female; mean age 50.3±16) with type 2 DM who used Sodium Glucose Co-Transporter-2 Inhibitor (SGLT-2), dapagliflozin, were enrolled into the study. Patients’ data such as laboratory materials, electrocardiographic findings and drugs, were compared between the initiation of dapagaliflozin treatment and in the first control (mean time 2.2 months after the initiation). Findings: Patients drugs were similar at the initiation of treatment and surveillance. Glucose, triglycerides, low-density lipoprotein, eGFR, and hemoglobin A1c levels were significantly lower after the treatment (p 0.05). Only heart rate was found to be significantly lower after the therapy (79.9/min vs 76.2/min, respectively) (p=0.02).

Subjects

Cardiology

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalInternational Journal of Cardiovascular Research
  • SubjectCardiology
  • BylineArticles whose byline prints “Gamze Akkus”